Seminars in Pediatric Neurology
Volume 12, Issue 1 , Pages 59-66 , March 2005

The Treatment of Cardiac Causes of Sudden Death, Syncope, and Seizure

  • Robert M. Campbell, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Robert M. Campbell, MD, Sibley Heart Center Cardiology, 52 Executive Park South, Suite 5200, Atlanta, GA 30329.

References 

  1. Campbell RM , Strieper MJ , Frias PA , et al.   Current status of radiofrequency ablation for common pediatric supraventricular tachycardias . J Pediatr . 2002;140:150–155
  2. Mirowski M , Reid PR , Mower MM , et al.   Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings . N Engl J Med . 1980;303:322–324
  3. Gregoratos G , Abrams J , Epstein AE , et al.   ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices; summary article (A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines)) . Circulation . 2002;160:2145–2161
  4. Steffanelli CB , Bradley DJ , Leroy S , et al.   Implantable cardioverter defibrillator therapy for life-threatening arrhythmias in young patients . J Interv Card Electrophysiol . 2002;6:235–244
  5. Alexander ME , Cecchin F , Walsh EP , et al.   Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics . J Cardiovasc Electrophysiol . 2004;15:72–76
  6. Luedemann M , Hund K , Stertmann W , et al.   Implantable cardioverter defibrillator in a child using a single subcutaneous array lead and an abdominal active can . PACE . 2003;27:117–119
  7. Gradaus R , Hammel D , Kotthoff S , et al.   Nonthoracotomoy implantable cardioverter defibrillator placement in children (use of subcutaneous array leads and abdominally placed in implantable cardioverter defibrillators in children) . J Cardiovasc Electrophysiol . 2001;12:356–360
  8. Sears SF , Burns JL , Handberg E , et al.   Young at heart (understanding the unique psychosocial adjustment of young implantable cardioverter defibrillator recipients) . PACE . 2001;24:113–117
  9. Maron BJ , Isner J , McKenna WJ . 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse . J Am Coll Cardiol . 1994;24:880–885
  10. Maron BJ , Chaitman BR , Ackerman MJ , et al.   Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular disease . Circulation . 2004;109:2807–2816
  11. Samson RA , Berg RA , Bingham R , et al.   Use of automated external defibrillators for children: an update: an advisory statement from the pediatric advance life support task force, International Liaison Committee on Resuscitation . Circulation . 2003;107:3250–3255
  12. Cecchin F , Jorgenson DB , Berul CI , et al.   Is arrhythmia detection by automatic external defibrillator accurate for children? Sensitivity and specificity of an automatic external defibrillator algorithm in 696 pediatric arrhythmias . Circulation . 2001;103:2483–2488
  13. Boucek MM , Edwards LB , Keck BM , et al.   Registry for the international society for heart and lung transplantation (seventh official pediatric report—2004) . J Heart Lung Transplant . 2004;23:933–947
  14. Maron BJ , McKenna WJ , Danielson GK , et al.   ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy (a report of the American College of Cardiology Task Force on clinical expert consensus documents and the European Society of Cardiology Committee for practice guidelines (committee to develop an expert consensus on hypertrophic cardiomyopathy)) . J Am Coll Cardiol . 2003;42:1–25 (Table 2)
  15. Maron MS , Olivotto I , Betocchi S , et al.   Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy . N Engl J Med . 2003;348:295–303
  16. Yetman AT , McCrindle BW , MacDonald C , et al.   Myocardial bridging in children with hypertrophic cardiomyopathy—a risk factor for sudden death . N Engl J Med . 1998;339:1201–1209
  17. Moon JC , McKenna WJ , McCrohon JA , et al.   Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance . J Am Coll Cardiol . 2003;41:1561–1567
  18. Spirito P , Bellone P , Harris KM , et al.   Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy . N Engl J Med . 2000;342:1778–1785
  19. Cecchi F , Olivotto I , Montereggi A , et al.   Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy (assessment in an unselected non-referral based patient population) . Heart . 1998;79:331–336
  20. Maron BJ , Shen WK , Lind MS , et al.   Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy . N Engl J Med . 2000;342:365–373
  21. Daliento L , Turrini P , Nava A , et al.   Arrhythmogenic right ventricular cardiomyopathy in young versus adult patients (similarities and differences) . J Am Coll Cardiol . 1995;25:655–664
  22. Turrini P , Corrado D , Basso C , et al.   Noninvasive risk stratification in arrhythmogenic right ventricular cardiomyopathy . Ann Noninvasive Electrocardiol . 2003;8:161–169
  23. Wichter T , Borggrefe M , Hoverkamp W , et al.   Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia . Circulation . 1992;86:29–37
  24. Kusano KF , Emori T , Morita H , et al.   Ablation of ventricular tachycardia by isolating the critical site in a patient with arrhythmogenic right ventricular cardiomyopathy . J Cardiovasc Electrophysiol . 2000;11:102–105
  25. Corrado D , Leoni L , Link MS , et al.   Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia . Circulation . 2003;108:3084–3091
  26. Wichter T , Paul M , Wollmann C , et al.   Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy (single-center experience of long-term follow-up and complications in 60 patients) . Circulation . 2004;109:1503–1508
  27. Priori SG , Napolitano C , Gasparini M , et al.   Natural history of Brugada syndrome . Circulation . 2002;105:1342–1347
  28. Brugada J , Brugada R , Antzelevitch C , et al.   Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3 . Circulation . 2002;105:73–78
  29. Suzuki H , Torigoe K , Numata O , et al.   Infant case with a malignant form of Brugada syndrome . J Cardiovasc Electrophysiol . 2000;11:1277–1280
  30. Priori SG , Napolitano C , Giordano U , et al.   Brugada syndrome and sudden cardiac death in children . Lancet . 2000;355:808–809
  31. Priori SG , Napolitano C , Memmi M , et al.   Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia . Circulation . 2002;106:69–74
  32. Sumitaomo N , Harada K , Nagashima M , et al.   Catecholaminergic polymorphic ventricular tachycardia (electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death) . Heart . 2003;89:66–70
  33. Leenhardt A , Lucet V , Denjoy I , et al.   Catecholaminergic polymorphic ventricular tachycardia in children . Circulation . 1995;91:1512–1519
  34. Priori SG , Schwartz PJ , Napolitano C , et al.   Risk stratification in the long QT syndrome . N Engl J Med . 2003;348:1866–1874
  35. Yoshinaga M , Hagashima M , Shibata T , et al.   Who is at risk for cardiac events in young patients with long QT syndrome? . Circ J . 2003;67:1007–1012
  36. Schwartz PJ . The long QT syndrome . Curr Probl Cardiol . 1997;22:297–351
  37. Schwartz PJ , Locati E . The idiopathic long QT syndrome (pathogenetic mechanisms and therapy) . Eur Heart J . 1985;6(suppl D):103–114
  38. Moss AJ , Zareba W , Hall WJ , et al.   Effectiveness and limitations of beta-blocker therapy in congenital long QT syndrome . Circulation . 2000;101:616–635
  39. Benhorin J , Taub R , Goldmit M , et al.   Effects of flecainide in patients with new SCN5A mutation (mutation-specific therapy for long-QT syndrome?) . Circulation . 2000;101:1698–1706
  40. Wang LX . Role of left cardiac sympathetic denervation in the management of congenital long QT syndrome . J Postgrad Med . 2003;49:179–181
  41. Eldar M , Griffin JC , Van Hare GF , et al.   Combined use of beta-adrenergic blocking agents and long-term cardiac pacing for patients with the long QT syndrome . J Am Coll Cardiol . 1992;20:830–837
  42. Moss AJ , Liu JE , Gottlieb S , et al.   Efficacy of permanent pacing in the management of high-risk patients with long QT syndrome . Circulation . 1991;84:1524–1529
  43. Zareba W , Moss AJ , Daubert JP , et al.   Implantable cardioverter defibrillator in high-risk long QT syndrome patients . J Cardiovasc Electrophysiol . 2003;14:337–341

PII: S1071-9091(05)00003-3

doi: 10.1016/j.spen.2005.01.002

Seminars in Pediatric Neurology
Volume 12, Issue 1 , Pages 59-66 , March 2005

Article Tools

* Image Usage & Resolution